Financial Performance - The company's revenue for Q3 2022 was CNY 216,398,655.98, representing a year-on-year increase of 53.43%[4] - The net profit attributable to shareholders for Q3 2022 was CNY 21,632,131.06, a decrease of 41.84% compared to the same period last year[4] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.1382, down 41.42% year-on-year[5] - Total operating revenue for the first three quarters of 2022 was CNY 587,989,983.65, a decrease of 1.02% compared to CNY 596,601,169.14 in the same period of 2021[18] - Net profit for the third quarter of 2022 was CNY 114,524,803.30, down 19.5% from CNY 142,273,626.25 in the same quarter of 2021[19] - Earnings per share (EPS) for the third quarter was CNY 0.6625, compared to CNY 0.8703 in the same period last year, reflecting a decline of 23.8%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,350,352,713.22, a decrease of 0.62% from the end of the previous year[5] - As of September 30, 2022, the company's total assets amounted to RMB 3,350,352,713.22, a slight decrease from RMB 3,371,320,206.37 at the end of 2021[14] - The company's cash and cash equivalents decreased to RMB 526,088,665.20 from RMB 599,081,775.25 year-over-year[14] - Accounts receivable stood at RMB 212,813,423.96, down from RMB 233,989,936.89 in the previous year[14] - Inventory decreased to RMB 36,771,327.00 from RMB 47,020,733.62 year-over-year[15] - The total current liabilities include accounts payable of RMB 34,082,140.55, down from RMB 46,738,357.06[15] - The company reported a total current asset of RMB 877,523,434.86, a decrease from RMB 947,828,654.54[15] - Total liabilities decreased to CNY 204,309,057.31 from CNY 240,742,477.76, indicating a reduction of approximately 15.1%[17] - Total equity increased slightly to CNY 3,146,043,655.91 from CNY 3,130,577,728.61, showing a growth of 0.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was CNY 131,673,194.89[4] - Cash flow from operating activities for the first three quarters was CNY 637,284,307.52, an increase of 16.6% from CNY 546,405,533.47 in the previous year[21] - The net cash flow from operating activities was ¥131,673,194.89, a significant improvement compared to a negative cash flow of ¥13,107,096.52 in the previous year[22] - Total cash inflow from investment activities was ¥197,467,082.77, down from ¥545,031,259.27 year-over-year[22] - The net cash flow from investment activities was -¥148,145,514.08, an improvement from -¥337,588,982.48 in the same quarter last year[22] - Cash flow from financing activities resulted in a net outflow of -¥56,294,706.10, compared to a net inflow of ¥190,243,324.15 in the previous year[23] - The ending balance of cash and cash equivalents was ¥522,898,916.48, down from ¥949,024,851.44 year-over-year[23] Expenses and Income - The company experienced a significant increase in management expenses by approximately CNY 5 million and R&D expenses by approximately CNY 1 million, impacting net profit[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period was CNY 55,929,753.17, down 53.48% year-on-year[4] - The company reported a decrease in other income by CNY 670,540 compared to the previous year, primarily due to reduced government subsidies[9] - Total operating costs increased to CNY 506,473,397.64, up 9.8% from CNY 461,334,304.84 in the previous year[18] - Research and development expenses for the first three quarters were CNY 54,706,235.57, down 17.7% from CNY 66,439,112.06 in the previous year[18] - The company reported an investment income of CNY 28,272,233.60, significantly up from CNY 6,625,700.59 in the same period of 2021[18] - Other comprehensive income after tax for the third quarter was CNY -57,580,557.97, an improvement compared to CNY -184,425,114.31 in the previous year[20] Clinical Trials and Research - The company announced the approval of the ethical review for the Phase III clinical trial of Jincao Tablets on September 28, 2022[13] - The company is in discussions with Alvogen, Inc. regarding the clinical trial application for Teriparatide injection, which was withdrawn for further documentation[13] - The company plans to disclose further updates on the clinical trial progress of Jincao Tablets as it advances[13]

Financial Performance - The basic earnings per share for the first half of 2022 was CNY 0.52, a decrease of 17.46% compared to CNY 0.63 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.52, reflecting the same percentage decrease of 17.46% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 60.60% compared to the previous year[21]. - The weighted average return on net assets was 2.86%, down by 0.50 percentage points from 3.36% in the same period last year[21]. - The company's operating revenue for the first half of the year was ¥371,591,327.67, a decrease of 18.43% compared to ¥455,557,666.78 in the same period last year[23]. - The net profit attributable to shareholders for the reporting period was ¥82,038,066.91, down 17.98% from ¥100,022,515.60 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥34,355,332.24, reflecting a significant decline of 60.60% compared to ¥87,201,380.13 in the previous year[23]. - The company reported a significant decrease in accounts receivable financing by 56.21%, down to ¥4,549,159.52, which is 0.14% of total assets[60]. - The company reported a net loss of approximately ¥46.95 million during the current period, reflecting a significant decrease compared to the previous period[151]. Cash Flow and Assets - The cash flow from operating activities increased compared to the same period last year, mainly due to a reduction in promotional service fees[21]. - The net cash flow from operating activities was ¥66,254,643.36, a notable improvement from a negative cash flow of ¥29,584,739.27 in the previous year[23]. - The company's cash and cash equivalents decreased by 6.30% to ¥561,359,820.33, representing 16.84% of total assets[60]. - The total cash and cash equivalents at the end of the period were ¥558,196,657.13, down from ¥980,979,883.10 at the end of the first half of 2021[143]. - The company reported a decrease in cash received from investment recoveries, totaling ¥189,373,420.33 compared to ¥479,585,264.66 in the first half of 2021[143]. - The company's total assets at the end of the reporting period were ¥3,333,060,355.19, down 1.13% from ¥3,371,320,206.37 at the end of the previous year[23]. - The company's total assets reached CNY 2,883,933,542.20, indicating a stable asset base despite the financial losses[157]. Research and Development - R&D expenses amounted to CNY 81.45 million, representing 21.92% of total revenue, with a significant increase of 50.61% year-on-year[52]. - The company is focusing on innovative drug development, with multiple new multi-target receptor tyrosine kinase inhibitors under research, including KC1036, CX1003, KC-B173, CX1026, and Jin Cao Pian[35][36][37][38][39][40][41][42]. - The company plans to enhance its R&D pipeline by collaborating with renowned domestic and international enterprises and research institutions[70]. - The company is focusing on key oncology drug development projects, aiming for expedited market entry through "pressure management" and increased R&D investment[70]. Market and Product Development - The company's main products include "Suling," a leading hemostatic agent, and "Mige Xi," a unique drug for preventing acute bone loss, both of which have established significant market positions[27][30]. - "Suling" has been widely used in over 2,000 hospitals across 31 provinces, helping millions of patients and saving nearly 100 tons of plasma annually[28]. - The company aims to enhance its market presence and profitability through continuous innovation and high-quality product development[27]. - The company plans to leverage its marketing capabilities to enhance sales of the acquired product "Mi Gai Xi," aiming for rapid business growth in the salmon calcitonin market[69]. Corporate Governance and Compliance - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[5]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[7]. - The company has not faced any environmental issues or administrative penalties during the reporting period, emphasizing its commitment to green production and sustainable development[82]. - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management and energy management systems[83]. - The company has committed to ensuring that the compensation measures for diluted immediate returns are effectively implemented by linking the remuneration system to the execution of these measures[101]. Strategic Partnerships and Acquisitions - The company has established strategic partnerships with German biotechnology firms and WuXi AppTec to enhance its product pipeline[49]. - The company has made performance commitments for the acquisition of "Mi Gai Xi" assets, with net profits of at least RMB 0.8 billion, 1 billion, and 1.2 billion for the years 2021, 2022, and 2023 respectively, totaling no less than RMB 3 billion over three years[102]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[150]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 17,241[117]. - The company completed the transfer of 1,994,900 shares to the first phase employee stock ownership plan at a price of 31.54 yuan per share, with a lock-up period of 36 months starting from the transfer date[80]. - The company has a profit forecast and compensation commitment for the period from 2021 to 2023[91]. - The company will announce any share reductions by Mu Ren Investment three trading days in advance, ensuring compliance with public commitments made during the IPO[99]. Financial Statements and Accounting Policies - The financial statements have been prepared based on the going concern assumption, indicating no significant issues affecting the company's ability to continue operations for at least 12 months[173]. - The company’s accounting policies comply with the requirements of the enterprise accounting standards, ensuring a true and complete reflection of its financial status[175]. - The preparation of consolidated financial statements is based on control, including subsidiaries determined by voting rights or contractual arrangements[182].

Financial Performance - The company's operating revenue for 2021 was approximately ¥809.78 million, a slight increase of 0.14% compared to ¥808.64 million in 2020[24]. - The net profit attributable to shareholders decreased by 19.29% to ¥147.99 million in 2021 from ¥183.36 million in 2020[24]. - The basic earnings per share for 2021 was ¥0.94, down 18.26% from ¥1.15 in 2020[25]. - The total assets at the end of 2021 were approximately ¥3.37 billion, a decrease of 10.95% from ¥3.79 billion at the end of 2020[24]. - The net cash flow from operating activities increased by 21.41% to ¥70.91 million in 2021 from ¥58.41 million in 2020[24]. - The company reported a weighted average return on equity of 5.02% for 2021, down from 6.51% in 2020[25]. - The net profit after deducting non-recurring gains and losses was ¥114.19 million, a decrease of 24.03% compared to ¥150.31 million in 2020[24]. - The company experienced a significant decline in net assets attributable to shareholders, which decreased by 6.16% to approximately ¥2.89 billion at the end of 2021[24]. - The fourth quarter of 2021 saw a net profit attributable to shareholders of ¥10.77 million, a significant drop compared to previous quarters[26]. - The company achieved a total revenue of CNY 809.78 million in 2021, representing a slight increase of 0.14% year-on-year[89]. - The net profit attributable to the parent company was CNY 147.99 million, a decrease of 19.29% compared to the previous year[89]. Research and Development - The company increased its R&D investment to CNY 164.89 million, a significant growth of 77.09% compared to the same period in 2020, accounting for 20.36% of its revenue[34]. - The company has established a talent team to enhance its original drug development capabilities, focusing on high-level talent acquisition and training[48]. - The company is focusing on innovative drug development in response to unmet clinical needs, including chemical drugs, biological drugs, and traditional Chinese medicine[34]. - The company is actively developing multiple innovative drugs, including KC1036, targeting AXL receptor tyrosine kinase and VEGFR2[119]. - The company has ongoing R&D projects, including KC1036 and CX1003, with respective investments of RMB 57.79 million and RMB 31.55 million, showing a significant increase of 121.22% and 85.67% compared to the previous year[140]. - The capitalized R&D expenditure accounted for 37.98% of total R&D investment, with RMB 62.62 million capitalized during the reporting period[136]. - The company is increasing R&D investment and collaborating with renowned domestic and international enterprises and research institutions to accelerate its R&D pipeline[156]. Product Development and Market Strategy - The innovative drug KC1036 has shown promising clinical progress, entering Phase Ib/II trials, with potential applications in esophageal cancer, thymic cancer, and cholangiocarcinoma[37]. - The company is actively expanding its product pipeline, with key products like KC-B173 and Jin Cao Pian entering clinical research stages, enhancing its market competitiveness[39]. - Jin Cao Pian, a traditional Chinese medicine, has completed Phase II clinical trials, demonstrating good safety and efficacy in treating chronic pelvic pain, with plans to submit for Phase III trials[40]. - The strategic plan for 2019-2028 aims to transition from a single product focus to a multi-product strategy, with a goal of launching multiple self-developed innovative drugs by 2026-2028[33]. - The company is leveraging its experience in the field of hemostatic agents to enter the pet medicine market, aiming to meet the demand for canine injectable hemostatic agents[38]. - The company is committed to maximizing the product lifecycle of its existing products while continuously expanding its product structure through strategic collaborations[39]. - The company is focusing resources on key R&D projects such as KC1036, "Jincao Tablets," and "Canine Injectable Hemostatic Agent" to achieve timely market launches[152]. Market Performance and Challenges - "苏灵" sales revenue decreased by 28.78% year-on-year due to policy changes and market conditions[42]. - The ongoing pandemic has impacted the sales volume of "Suling," as the utilization rate of hospital beds was only 75.1% by the end of 2021, affecting surgical procedures[81]. - The company aims to maintain and expand the market share of its leading product "Suling," which is the highest-selling hemostatic drug in the domestic market, despite price reductions from national insurance negotiations[155]. - The company is expanding its sales channels for "Mikexi" through academic guidance and online sales initiatives, aiming to enhance product accessibility and recognition among healthcare professionals and patients[80]. Governance and Compliance - The company has established a governance structure that ensures compliance with laws and regulations, protecting the interests of all shareholders[160]. - The company is committed to transparent information disclosure and maintaining effective communication with investors[162]. - The company strictly adhered to the insider information management system, ensuring confidentiality and proper registration of insiders during the reporting period[163]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating compliance with regulations[178]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[163]. Shareholder Engagement and Remuneration - The company plans to implement a three-year shareholder return plan from 2021 to 2023, which was approved in the meetings[166]. - The total pre-tax remuneration for all listed directors and supervisors amounted to 5,379,000 RMB[170]. - The remuneration for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[175]. - The company ensures that minority shareholders have the opportunity to express their opinions and that their legal rights are fully protected[200]. Strategic Partnerships and Collaborations - The company has signed a cooperation agreement with WuXi AppTec for the development of KC1072, further enhancing its oncology product line[41]. - The company has formed strategic partnerships with various research institutions to enhance its innovative drug development capabilities[53]. - The company has established strategic partnerships with international firms to enrich its product pipeline, including collaborations with German biotech companies[86].

Financial Performance - The company's operating revenue for Q1 2022 was ¥156,191,778.75, representing a decrease of 25.99% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2022 was ¥46,436,981.84, down 27.89% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥6,884,680.06, a significant decline of 88.74%[5] - Basic and diluted earnings per share for Q1 2022 were both ¥0.30, a decrease of 26.83%[6] - In Q1 2022, the company's net profit was CNY 50,440,303.82, a decrease of 21.6% compared to CNY 64,395,066.77 in Q1 2021[22] - The total revenue from operating activities was CNY 235,245,392.87, down 10.5% from CNY 262,836,445.33 in the same period last year[25] - The company's total comprehensive income for Q1 2022 was CNY 31,295,350.69, compared to a loss of CNY 67,892,684.49 in Q1 2021[23] Cash Flow and Assets - The net cash flow from operating activities increased by 82.23%, amounting to ¥57,190,059.97[5] - Cash and cash equivalents as of March 31, 2022, were RMB 538,783,262.66, down from RMB 599,081,775.25 at the end of 2021[15] - The cash and cash equivalents at the end of Q1 2022 were CNY 826,389,336.17, down from CNY 962,851,329.42 at the end of Q1 2021[27] - Total assets at the end of the reporting period were ¥3,362,120,574.65, a slight decrease of 0.27% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 3,362,120,574.65, a slight decrease from RMB 3,371,320,206.37 at the end of 2021[18] Expenses and Liabilities - Total operating costs for Q1 2022 were RMB 127,527,189.83, down from RMB 142,364,608.25 in Q1 2021, reflecting a cost reduction strategy[21] - Sales expenses in Q1 2022 amounted to RMB 71,535,482.12, a decrease of 23% from RMB 93,320,858.76 in Q1 2021[21] - Research and development expenses for Q1 2022 were RMB 16,729,400.94, slightly up from RMB 16,068,231.02 in Q1 2021, indicating continued investment in innovation[21] - Total liabilities decreased to RMB 198,424,463.66 as of March 31, 2022, compared to RMB 240,742,477.76 at the end of 2021[18] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 1.01% to ¥2,917,879,941.58[6] - The company's equity attributable to shareholders increased to RMB 2,917,879,941.58 as of March 31, 2022, from RMB 2,888,764,881.18 at the end of 2021[18] Non-Recurring Gains and Future Outlook - The decline in net profit after deducting non-recurring gains was primarily due to the new medical insurance negotiation price for "Su Ling," leading to reduced sales prices and revenue impacts from the ongoing pandemic[10] - The company reported non-recurring gains totaling ¥39,552,301.78 after tax, with significant contributions from government subsidies and other non-operating income[9] - The company reported a net profit margin improvement due to cost control measures, although specific profit figures were not disclosed[21] - Future outlook includes a focus on market expansion and potential new product launches, although specific details were not provided in the report[21] Investment and Tax - The company reported an investment loss of CNY 114,983,877.92 in Q1 2022, compared to a loss of CNY 101,677,003.56 in Q1 2021[26] - The company incurred interest expenses of CNY 208,726.16 in Q1 2022, compared to CNY 358,055.88 in Q1 2021, reflecting a decrease of 41.7%[22] - The company reported a tax expense of CNY 3,907,909.27 in Q1 2022, down from CNY 8,720,966.12 in Q1 2021, indicating a decrease of 55.2%[22] - The company paid CNY 49,286,660.61 in employee compensation during Q1 2022, an increase from CNY 33,763,839.98 in Q1 2021[26]

2021 年第三季度报告 证券代码：603590 证券简称：康辰药业 北京康辰药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | | | | | 单位：元 币种：人民币 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 141,043,502.36 | -30.1 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[22]. - The net profit for the first half of 2021 was RMB 100 million, which is a 30% increase compared to the same period last year[22]. - The company's operating revenue increased by 30.91% year-on-year, reaching approximately ¥455.56 million, primarily due to the revenue generated from the acquisition of the "Mige Xi" asset business[24]. - The net profit attributable to shareholders decreased by 2.94% year-on-year, amounting to approximately ¥100.02 million[24]. - The company's revenue for the first half of 2021 reached 456 million yuan, an increase of 30.91% year-on-year[44]. - The net profit attributable to the parent company was 100 million yuan, a decrease of 2.94% year-on-year[44]. - The company reported a total revenue of CNY 362,594,788.56 for the current period, compared to CNY 453,314,663.19 in the same period last year, reflecting a decrease of approximately 20%[157]. - The company reported a net profit of RMB 3.97 million from Tai Ling International Pharmaceutical Co., Ltd., which was acquired in September 2020, contributing to new revenue growth[65]. Research and Development - Research and development expenses increased by 20%, totaling RMB 50 million, reflecting the company's commitment to innovation and new technology[22]. - The company has significantly increased its R&D investment, with R&D expenses rising year-on-year, indicating a focus on innovation[38]. - Research and development expenses rose to RMB 54.08 million, representing a 44.7% increase from RMB 37.32 million in the previous year[147]. - The company aims to enhance its core competitiveness in the oncology drug market through a robust pipeline of targeted anti-tumor drug products[29]. - The clinical trial for KC1036 has shown promising results, with 2 patients experiencing partial remission, and the project is currently in the dose escalation phase[48]. Market Expansion and Product Development - User data indicates that the company has expanded its customer base by 15%, now serving over 1 million active users[22]. - The company plans to launch two new products in the second half of 2021, aiming to capture an additional 10% market share in the pharmaceutical sector[22]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 5% increase in international sales by the end of 2021[22]. - The company has entered the orthopedic drug market through the acquisition of "Mige Xi," which includes a salmon calcitonin product for osteoporosis treatment, enhancing its product portfolio and providing new profit growth points[30]. - The company aims to expand the market share of its leading product "Su Ling" to offset the impact of price reductions from medical insurance negotiations[67]. Financial Position and Assets - The total assets of the company decreased by 7.34% year-on-year, totaling approximately ¥3.51 billion[24]. - The net assets attributable to shareholders decreased by 6.63% year-on-year, amounting to approximately ¥2.87 billion[24]. - The company's cash and cash equivalents as of June 30, 2021, amount to RMB 1,064,346,802.73, down from RMB 1,346,668,808.43 at the end of 2020[139]. - Total assets as of June 30, 2021, amounted to CNY 3,507,942,572.98, a decrease from CNY 3,785,661,037.14 at the end of 2020, representing a decline of approximately 7.3%[140]. - The company's total equity as of June 30, 2021, was CNY 2,883,933,542.20, down from CNY 3,083,936,196.19, indicating a decrease of approximately 6.5%[141]. Shareholder Commitments and Governance - The actual controllers Liu Jianhua and Wang Xijuan committed to not transferring or entrusting their shares for 36 months from the date of the company's stock listing[90]. - Liu Jianhua and Wang Xijuan will not transfer more than 25% of their shares annually while serving as directors or senior management[90]. - The company has established measures to prevent related party transactions that could harm its interests[89]. - The company will ensure that any related party transactions do not illegally transfer funds or profits, protecting the interests of the company and its shareholders[94]. - The company has signed a lease agreement with an affiliate for a research office space of 4,015.45 square meters at a rental rate of 4.00 RMB per square meter per day, with an estimated annual rent of 5,862,557.00 RMB[113]. Compliance and Environmental Responsibility - The company has not faced any environmental penalties and has maintained compliance with environmental regulations[80]. - The company has completed a self-declaration for the "Green Factory Demonstration" on the Ministry of Industry and Information Technology platform[81]. - The company has undertaken measures to reduce carbon emissions by replacing steam heating with air-source heat pumps[84]. - The financial statements comply with the enterprise accounting standards, reflecting the company's financial position and operating results accurately[185]. Employee and Management Changes - The workforce has been strengthened with the recruitment of over 20 elite talents in the first half of 2021, supporting the company's strategic development[50]. - The company experienced a change in senior management, with the resignation of the board secretary, Tang Zhison[74]. - The company has implemented an employee stock ownership plan, with 1,994,900 shares transferred at a price of 31.54 yuan per share[77].

1.4 本公司第一季度报告未经审计。 2021 年第一季度报告 公司代码：603590 公司简称：康辰药业 北京康辰药业股份有限公司 2021 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 2021 年第一季度报告 非经常性损益项目和金额 二、 公司基本情况 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 越权审批，或无正式批准文件，或 | -731.59 | | | 偶发性的税收返还、减免 | | | | 计入当期损益的政府补助，但与公 | | | | 司正常经营业务密切相关，符合国 | 1,997,938.64 | | | 家政策规定、按照一定标准定额或 | | | | 定量持续享受的政府补助除外 | | | | 计入当期损益的对非金融企业收取 | | | | 的资金占用费 | | | | 企业取得子公司、联营企业及合营 | | | ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥808.64 million, a decrease of 24.14% compared to ¥1,065.92 million in 2019[21]. - Net profit attributable to shareholders decreased by 31.09% to ¥183.36 million from ¥266.08 million in 2019[22]. - The basic earnings per share fell by 30.72% to ¥1.15, down from ¥1.66 in the previous year[22]. - The net cash flow from operating activities decreased significantly by 77.71% to ¥58.41 million, compared to ¥262.00 million in 2019[22]. - Total assets increased by 19.28% to ¥3,785.66 million at the end of 2020, up from ¥3,173.84 million at the end of 2019[21]. - The company's net assets attributable to shareholders rose by 12.84% to ¥3,078.34 million from ¥2,727.99 million in 2019[21]. - The weighted average return on equity decreased by 3.74 percentage points to 6.51% from 10.25% in 2019[22]. - The company reported a significant reduction in non-recurring gains and losses, with a total of ¥33.04 million in 2020 compared to ¥31.47 million in 2019[27]. - The company experienced a decline in revenue due to the impact of the pandemic, affecting both sales and collections[22]. - The company's main product, "Su Ling" (injection of Agkistrodon Acutus snake venom), saw a revenue decrease of 24.76% compared to the previous year, totaling approximately ¥792.23 million[59]. Dividend Policy - The company plans to distribute a cash dividend of RMB 3.50 per 10 shares to all shareholders, subject to approval at the shareholders' meeting[5]. - The proposed cash dividend for 2020 is RMB 55,182,802.15, which translates to RMB 3.50 per 10 shares (tax included)[115]. - The total cash dividend, including share repurchase, amounts to RMB 74,500,905.00, representing 70.73% of the net profit attributable to ordinary shareholders[118]. - The cash dividend payout ratio for 2019 was 30.07%, with a total cash dividend of RMB 266,080,142.06[115]. - The cash dividend payout ratio for 2018 was 30.31%, with a total cash dividend of RMB 263,929,840.55[115]. Corporate Governance - The company reported a standard unqualified audit opinion from Huaxing Accounting Firm for the fiscal year 2020[4]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The report indicates that the company has maintained a commitment to the accuracy and completeness of its financial disclosures, with all board members present at the meeting[8]. - The company's actual controllers are Liu Jianhua and Wang Xijuan, with Liu Jianhua being the controlling shareholder[11]. - The company has established commitments to avoid competition with its controlling shareholders' other businesses[123]. - Liu Jianhua and Wang Xijuan pledged to regulate and minimize related party transactions, ensuring they do not adversely affect the company or other shareholders[125]. Research and Development - The company focuses on innovative drug research and development, particularly in the fields of hematology, orthopedics, and oncology, with its main product "Suling" being the only national class I new drug in the domestic hemostatic agent market[30]. - The company aims to enhance its innovative drug development process and quality management systems to improve project development speed and quality[82]. - The company has a robust pipeline of innovative drugs, with several projects in various stages of development, including I phase and preclinical[84]. - The company received clinical trial notification for the KC1036 project and entered Phase I clinical research in 2020[50]. - In 2020, the company invested CNY 93.1072 million in research and development, significantly supporting project development and innovation[83]. - Research and development expenses totaled ¥93.11 million, accounting for 11.51% of total revenue, with a decrease of 14.41% compared to the previous year[66]. Market Strategy - The company plans to focus on new product development and market expansion strategies to recover from the downturn[29]. - The marketing team successfully negotiated to include "Suling" in the National Basic Medical Insurance Drug List (2020), which is expected to enhance market share[48]. - The company aims to expand the market share of its product "Su Ling" through negotiations with medical insurance, targeting both existing and new hospital markets[106]. - The company utilizes a unique alliance model for sales, collaborating closely with specialized third-party academic promotion agencies to enhance market share[91]. Risk Management - The report emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements[6]. - The company has detailed potential risks in the report, which can be found in the section discussing operational conditions[7]. - The company faces market competition risks, particularly in maintaining the leading position of "Su Ling" after price negotiations[110]. - The company is also addressing new drug development risks, especially in the highly concentrated field of oncology innovation drugs[110]. Environmental and Social Responsibility - The company has received the title of National Green Factory in 2020, emphasizing its commitment to high-quality development and environmental responsibility[171]. - The company has actively participated in social welfare activities during the pandemic, including donations to various foundations and support for low-income areas[172]. - The company has established a leading drug safety management system covering the entire lifecycle of products from R&D to post-marketing[171]. - The company has not experienced any environmental pollution incidents during the reporting period and has not received any administrative penalties related to environmental protection[173]. - The company has established a hazardous waste and solid waste management system, ensuring proper disposal and compliance with environmental regulations[178]. Shareholder Information - The total number of ordinary shareholders increased from 13,877 to 14,375 during the reporting period[180]. - The largest shareholder, Liu Jianhua, holds 50,786,760 shares, representing 31.74% of the total shares[183]. - Liu Jianhua holds 58,466,760 shares, while Wang Xijuan holds 14,621,040 shares, with no changes in their holdings during the reporting period[194]. - The total pre-tax remuneration for the management team during the reporting period amounts to 538.45 million RMB[194].

Financial Performance - Operating revenue decreased by 27.75% to CNY 550,025,351.30 for the period from January to September[7] - Net profit attributable to shareholders decreased by 30.41% to CNY 141,758,055.44 for the same period[7] - Basic and diluted earnings per share decreased by 30.12% to CNY 0.8897[8] - Net profit after deducting non-recurring gains and losses decreased by 31.68% to CNY 121,988,161.58[7] - The weighted average return on equity decreased by 3.09 percentage points to 4.94%[7] - Total operating revenue for Q3 2020 was ¥202,021,985.97, a decrease of 7.5% compared to ¥217,664,838.37 in Q3 2019[25] - Net profit for Q3 2020 was ¥38,701,931.91, a decline of 28.8% from ¥54,299,256.04 in Q3 2019[27] - Earnings per share for Q3 2020 was ¥0.2456, compared to ¥0.3394 in Q3 2019[28] - The company reported a total comprehensive income of ¥71,716,427.38 for Q3 2020, down from ¥119,146,202.31 in Q3 2019[28] - The total comprehensive income for Q3 2020 was ¥80.46 million, down 33.7% from ¥121.27 million in Q3 2019[31] Cash Flow - Cash flow from operating activities decreased by 68.64% to CNY 65,450,208.91 compared to the previous year[7] - Operating cash flow for the first nine months of 2020 was 65,450,208.91 CNY, down 68.64% compared to 208,694,402.62 CNY in the same period of 2019, primarily due to decreased sales revenue and collections impacted by the pandemic[15] - The cash flow from operating activities for the first three quarters of 2020 totaled ¥784,827,983.47, down from ¥943,011,307.57 in the same period last year[35] - In Q3 2020, the company reported a net cash flow from operating activities of ¥89,620,336.90, a decrease of 57.6% compared to ¥210,081,197.89 in Q3 2019[36] - The company’s cash flow from financing activities showed a net outflow of ¥564,917,295.37, compared to a net outflow of ¥80,000,000.00 in Q3 2019[36] Assets and Liabilities - Total assets increased by 18.88% to CNY 3,773,001,207.71 compared to the end of the previous year[7] - Current assets decreased to 1,759,263,767.02 CNY from 2,098,369,476.02 CNY, reflecting a decline in cash and receivables[18] - Total liabilities increased to 811,011,835.71 CNY from 445,844,690.19 CNY, indicating a rise in current liabilities[20] - The company's total equity rose to 2,961,989,372.00 CNY from 2,727,998,110.33 CNY, showing growth in shareholder equity[20] - Total liabilities amounted to ¥445,844,690.19, while total equity reached ¥2,727,998,110.33, resulting in total assets of ¥3,173,842,800.52[41] Shareholder Information - The total number of shareholders at the end of the reporting period is not specified in the provided content[11] - Total number of shareholders reached 15,309[12] - Liu Jianhua holds 50,786,760 shares, accounting for 31.74% of total shares[12] Inventory and Receivables - Accounts receivable decreased by 31.92% to 147,110,830.93 due to collection of receivables[13] - Inventory increased by 145.44% to 34,984,454.67 due to higher stock levels[13] Other Financial Metrics - Government subsidies recognized during the period amounted to CNY 24,464,177.11[9] - Other non-recurring gains and losses totaled CNY 5,477,281.77 for the period[10] - Significant decrease in trading financial assets by 100% due to maturity of financial products[13] - Investment income increased by 35.54% to 11,640,477.47 due to higher dividend income[14] - Other comprehensive income increased by 558.02% to 203,030,251.51 due to changes in fair value of equity instruments[14] - Goodwill increased due to the acquisition of the Micai business[14]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥348,003,365.33, a decrease of 35.98% compared to ¥543,569,726.12 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥103,056,123.53, down 31.02% from ¥149,396,439.17 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥88,763,511.44, a decline of 34.97% compared to ¥136,487,861.87 in the same period last year[20]. - The net cash flow from operating activities was ¥82,925,821.00, which is a decrease of 39.59% from ¥137,270,455.25 in the previous year[20]. - Basic earnings per share decreased by 31.18% to CNY 0.64 compared to the same period last year[21]. - Net profit attributable to shareholders decreased by 31.02% year-on-year, primarily due to a 35.98% decrease in operating revenue[21]. - Operating cash flow decreased by 39.59% compared to the same period last year, mainly due to reduced cash received from sales of goods and services[21]. - The company’s weighted average return on equity decreased by 2.35 percentage points to 3.56%[21]. Assets and Liabilities - The net assets attributable to shareholders at the end of the reporting period were ¥2,914,400,462.35, an increase of 6.83% from ¥2,727,998,110.33 at the end of the previous year[20]. - The total assets at the end of the reporting period were ¥3,321,179,526.65, reflecting a growth of 4.64% compared to ¥3,173,842,800.52 at the end of the previous year[20]. - The total liabilities decreased to CNY 406,779,064.30 from CNY 445,844,690.19, indicating a reduction of about 8.7%[112]. - The company's total current assets reached CNY 2,247,004,313.25, up from CNY 2,098,369,476.02 at the end of 2019, reflecting a growth of approximately 7.1%[110]. Research and Development - The company has established a comprehensive R&D system and a professional international R&D team, enhancing its capability to develop innovative drugs[32]. - The company is focusing on developing targeted anti-tumor drug products to enhance its core competitiveness in a large market space[26]. - The company has a robust pipeline of three national class I anti-tumor drugs under development, with multiple patent applications filed domestically and internationally[34]. - The company is focusing on the development of innovative drugs, particularly in the fields of anti-tumor and hemostatic drugs, with multiple projects under development[41]. Marketing and Sales Strategy - The sales model has shifted to a distribution model, with a focus on collaboration with promotional service providers to maximize resource utilization[28]. - The company has established a highly efficient marketing operation management department to support sales and market academic promotion activities[28]. - The company employs an efficient alliance marketing model, maximizing resource utilization and efficiency through partnerships with promotional service providers[37]. Environmental Responsibility - The company emphasizes environmental protection and has not faced any environmental pollution incidents or administrative penalties during the reporting period[93]. - The company completed greenhouse gas emission verification and evaluations for material and water conservation in 2020[94]. - The company has established a water reuse pool and regularly disposes of hazardous waste through third-party services, ensuring compliance with environmental standards[94]. - The company has implemented an emergency response plan for environmental incidents, filed with the local ecological environment bureau[94]. Corporate Governance - The company held its first extraordinary general meeting on January 14, 2020, approving several resolutions including changes to the auditing institutions for the 2019 fiscal year[64]. - The second extraordinary general meeting on March 30, 2020, approved changes to the investment plan for the "Innovative Drug R&D and Targeted Antitumor Drug Innovation Platform" project[64]. - The company’s actual controllers committed to not transferring or managing their shares for 36 months post-IPO[69]. - The company’s board members are restricted to transferring no more than 25% of their shares annually during their tenure[70]. Financial Management - The company plans to repurchase shares with a total amount not exceeding the total funds raised from its initial public offering[83]. - The company provided a loan of RMB 380 million to its wholly-owned subsidiary, with a loan term of one year[88]. - The company’s financing activities saw a net cash outflow of CNY 152 million, an increase of 90.22% compared to the previous year, primarily due to increased cash used for share repurchases[48]. Shareholder Information - The total number of common shareholders as of the reporting period end was 15,123[99]. - The largest shareholder, Liu Jianhua, holds 50,786,760 shares, accounting for 31.74% of the total shares[101]. - The company distributed dividends amounting to ¥80,000,000.00 in the first half of 2020, consistent with the same period in 2019[134]. Compliance and Accounting - The financial statements comply with the requirements of the accounting standards, reflecting the company's financial position and operating results accurately[159]. - The company has not disclosed any changes in accounting policies or estimates during the reporting period[95]. - The company follows specific accounting policies for inventory valuation, fixed asset depreciation, and revenue recognition based on its operational characteristics[158].